Generic drug user fee increases may be hard to come by in the next round of program reauthorization talks amid questions about industry and the generic market health, as well as US Food and Drug Administration performance going forward.
GDUFA III reauthorization negotiations are expected to begin later this year in anticipation of the program's expiration in October 2022
The FDA has said no major issues are anticipated during the negotiations